Cogent Biosciences Inc [COGT] stock is trading at $4.30, down -1.60%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The COGT shares have gain 0.94% over the last week, with a monthly amount drifted -41.02%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cogent Biosciences Inc [NASDAQ: COGT] stock has seen the most recent analyst activity on March 07, 2025, when Scotiabank initiated its Sector Outperform rating and assigned the stock a price target of $17. Previously, Needham downgraded its rating to Hold on December 11, 2024. On February 26, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $8 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $11 on February 08, 2024. Wedbush downgraded its rating to a Neutral but $5 remained the price target by the analyst firm on December 11, 2023. JP Morgan started tracking with a Overweight rating for this stock on December 08, 2023, and assigned it a price target of $18. In a note dated April 28, 2023, Robert W. Baird initiated an Outperform rating and provided a target price of $20 on this stock.
Cogent Biosciences Inc [COGT] stock has fluctuated between $3.72 and $12.61 over the past year. Currently, Wall Street analysts expect the stock to reach $14 within the next 12 months. Cogent Biosciences Inc [NASDAQ: COGT] shares were valued at $4.30 at the most recent close of the market. An investor can expect a potential return of 225.58% based on the average COGT price forecast.
Analyzing the COGT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.78, Equity is -0.75 and Total Capital is -1.01. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.19 points at the first support level, and at 4.08 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.42, and for the 2nd resistance point, it is at 4.54.
Ratios To Look Out For
For context, Cogent Biosciences Inc’s Current Ratio is 5.32. Further, the Quick Ratio stands at 5.32, while the Cash Ratio is 1.76.
Transactions by insiders
Recent insider trading involved Pinnow Cole, Chief Commercial Officer, that happened on Jan 14 ’25 when 43750.0 shares were purchased.
